Table 1. Main baseline characteristics and clinical outcome of patients investigated for thrombocytosis.
| Patient | Age, gender | Prior Thrombosis (Y/N) |
Plt count ≥ 450 (× 109/l) |
BM histology |
JAK2V617F AB, % 1st evaluation |
JAK2V617F AB, % 2nd evaluation |
CALR |
Fulfilled 2008 WHO diagnostic criteria (Y/N) |
Final diagnosis | Therapy | Status at last follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | 20, F | N | Y | Y | 0.12 | 0.36 | WT | Y | ET | IFN | PLT < 400 |
| T2 | 46, M | Y | Y | Y | 0.79 | - | WT | Y | ET | IFN | PLT < 400 |
| T3 | 33, F | N | Y | Y | 0.20 | 1.46 | WT | Y | ET | - | PLT < 1000 |
| T4 | 25, F | N | Y | Y | 2.37 | - | WT | Y | ET | ASA | PLT <1000 |
| T5 | 62, M | Y | Y | Y | 2.98 | 7.38 | WT | Y | ET | HU, ASA | PLT < 600 |
| T6 | 17, M | N | Y | Y | 3.00 | - | WT | Y | ET | - | PLT <1000 |
| T7 | 50, F | N | Y | Y | 0.43 | - | WT | Y | Early-PMF | IFN | PLT < 400 |
| T8 | 31, M | N | Y | Y | 2.36 | - | WT | Y | Early-PMF | IFN | PLT < 400 |
| T9 | 46, M | N | Y | N.A. | 0.56 | - | Type1 (42%) |
N (absence of BM biopsy) | ET | HU | PLT < 600 |
| T10 | 38, F | N | Y | Y | 0.41 | - | WT | Y | ET | HU | PLT < 1000 |
| T11 | 57, F | N | Y | N.A. | 0.64 | 1.63 | WT | N (absence of BM biopsy) | Probable ET | ASA | PLT < 1000 |
| T12 | 66, M | N | Y | Y | 1.05 | - | WT | Y | ET | HU, ASA | PLT < 600 |
| T13 | 71, F | N | Y | N.A. | 1.56 | - | WT | N (absence of BM biopsy) | Probable ET | ASA | PLT < 400 |
| T14 | 91, F | Y | Y | N.A. | 2.38 | 9.20 | WT | N (absence of BM biopsy) | Probable ET | HU, ASA | PLT <400 |
| T15 | 72, F | Y | Y | N.A. | 0.32 | - | WT | N (absence of BM biopsy, evidence of reactive thrombocytosis) | Reactive (reumatoid arthritis) |
- | PLT < 600 |
| T16 | 81, M | N | Y | N.A. | 0.34 | - | WT | N (absence of BM biopsy, evidence of reactive thrombocytosis) | Reactive (reumatoid arthritis) |
- | PLT < 600 |
| T17 | 43, F | N | Y | N.A. | 0.59 | 0.50 | WT | N (absence of BM biopsy, evidence of reactive thrombocytosis) | Reactive (iron deficiency) |
IRON THERAPY | PLT < 400 |
| T18 | 25, F | N | Y | Y (normal) |
0.12 | WT | WT | N (normal BM histology, evidence of reactive thrombocytosis) | Reactive (erysipelas) |
- | PLT < 400 |
| T19 | 35, F | N | Y | Y (normal) |
0.61 | - | WT | N (normal BM histology, evidence of reactive thrombocytosis) | Reactive (iron deficiency) |
- | PLT < 600 |
Patients with persistent thrombocytosis in absence of other causes that did not perform BM biopsy for histological confirmation were classified as ‘’Probable ET’’. PLT: platelet (× 109/l); BM: bone marrow; N.A.: not available; ET: Essential Thrombocythemia; Early-PMF: early-primary myelofibrosis; WT: wild-type; HU: hydroxyurea; IFN: interferon-alpha; ASA: low-dose aspirin. Patient 19 had received splenectomy for a previous diagnosis of immune thrombocytopenia. Only in 5 cases, lactate dehydrogenase (LDH) was elevated. No patients had splenomegaly.